|
|
|
SB1371 Engrossed |
|
LRB096 10807 ASK 21022 b |
|
|
1 |
| AN ACT concerning regulation.
|
2 |
| Be it enacted by the People of the State of Illinois,
|
3 |
| represented in the General Assembly:
|
4 |
| Section 5. The Nurse Practice Act is amended by changing |
5 |
| Sections 65-5 and 65-40 as follows:
|
6 |
| (225 ILCS 65/65-5)
(was 225 ILCS 65/15-10)
|
7 |
| (Section scheduled to be repealed on January 1, 2018)
|
8 |
| Sec. 65-5. Qualifications for APN licensure.
|
9 |
| (a) Each applicant who successfully meets the requirements |
10 |
| of this Section shall be entitled to licensure as an advanced |
11 |
| practice nurse. |
12 |
| (b) An applicant for licensure to practice as an advanced |
13 |
| practice nurse must do each of the following:
|
14 |
| (1) Submit a completed application and any fees as |
15 |
| established by the Department.
|
16 |
| (2) Hold a current license to practice as a
registered |
17 |
| professional nurse under this Act.
|
18 |
| (3) Have successfully completed requirements to |
19 |
| practice as, and holds a
current, national certification |
20 |
| as, a nurse midwife, clinical nurse specialist,
nurse |
21 |
| practitioner, or certified registered nurse anesthetist |
22 |
| from the
appropriate national certifying body as |
23 |
| determined by rule of the Department.
|
|
|
|
SB1371 Engrossed |
- 2 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| (4) Have obtained a graduate degree appropriate for |
2 |
| national certification in a clinical advanced practice |
3 |
| nursing specialty or a graduate degree or post-master's |
4 |
| certificate from a graduate level program in a clinical |
5 |
| advanced practice nursing specialty.
|
6 |
| (5) Have not violated the provisions of this Act |
7 |
| concerning the grounds for disciplinary action. The |
8 |
| Department may take into consideration any felony |
9 |
| conviction of the applicant, but such a conviction may not |
10 |
| operate as an absolute bar to licensure. |
11 |
| (6) Submit to the criminal history records check |
12 |
| required under Section 50-35 of this Act.
|
13 |
| (b-5) A registered professional nurse seeking licensure as |
14 |
| an advanced practice nurse in the category of certified |
15 |
| registered nurse anesthetist who does not have a graduate |
16 |
| degree as described in subsection (b) of this Section shall be |
17 |
| qualified for licensure if that person: |
18 |
| (1) submits evidence of having successfully completed |
19 |
| a nurse anesthesia program described in item (4) of |
20 |
| subsection (b) of this Section prior to January 1, 1999; |
21 |
| (2) submits evidence of certification as a registered |
22 |
| nurse anesthetist by an appropriate national certifying |
23 |
| body; and |
24 |
| (3) has continually maintained active, up-to-date |
25 |
| recertification status as a certified registered nurse |
26 |
| anesthetist by an appropriate national recertifying body. |
|
|
|
SB1371 Engrossed |
- 3 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| (b-10) The Department shall issue a certified registered |
2 |
| nurse anesthetist license to an APN who (i) does not have a |
3 |
| graduate degree, (ii) applies for licensure before July 1, |
4 |
| 2018, and (iii) submits all of the following to the Department: |
5 |
| (1) His or her current State registered nurse license |
6 |
| number. |
7 |
| (2) Proof of current national certification, which |
8 |
| includes the completion of an examination from either of |
9 |
| the following: |
10 |
| (A) the Council on Certification of the American |
11 |
| Association of Nurse Anesthetists; or |
12 |
| (B) the Council on Recertification of the American |
13 |
| Association of Nurse Anesthetists. |
14 |
| (3) Proof of the successful completion of a post-basic |
15 |
| advanced practice formal education program in the area of |
16 |
| nurse anesthesia prior to January 1, 1999. |
17 |
| (4) His or her complete work history for the 5-year |
18 |
| period immediately preceding the date of his or her |
19 |
| application. |
20 |
| (5) Verification of licensure as an advanced practice |
21 |
| nurse from the state in which he or she was originally |
22 |
| licensed, current state of licensure, and any other state |
23 |
| in which he or she has been actively practicing as an |
24 |
| advanced practice nurse within the 5-year period |
25 |
| immediately preceding the date of his or her application. |
26 |
| If applicable, this verification must state: |
|
|
|
SB1371 Engrossed |
- 4 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| (A) the time during which he or she was licensed in |
2 |
| each state, including the date of the original issuance |
3 |
| of each license; and |
4 |
| (B) any disciplinary action taken or pending |
5 |
| concerning any nursing license held, currently or in |
6 |
| the past, by the applicant. |
7 |
| (6) The required fee. |
8 |
| (c) Those applicants seeking licensure in more than one |
9 |
| advanced practice nursing specialty need not possess multiple |
10 |
| graduate degrees. Applicants may be eligible for licenses for |
11 |
| multiple advanced practice nurse licensure specialties, |
12 |
| provided that the applicant (i) has met the requirements for at |
13 |
| least one advanced practice nursing specialty under paragraphs |
14 |
| (3) and (5) of subsection (a) of this Section, (ii) possesses |
15 |
| an additional graduate education that results in a certificate |
16 |
| for another clinical advanced practice nurse specialty and that |
17 |
| meets the requirements for the national certification from the |
18 |
| appropriate nursing specialty, and (iii) holds a current |
19 |
| national certification from the appropriate national |
20 |
| certifying body for that additional advanced practice nursing |
21 |
| specialty.
|
22 |
| (d) Any person who holds a valid license as an advanced |
23 |
| practice nurse issued under this Act as this Act existed before |
24 |
| the effective date of this amendatory Act of the 95th General |
25 |
| Assembly shall be subject only to the advanced practice nurse |
26 |
| license renewal requirements of this Act as this Act exists on |
|
|
|
SB1371 Engrossed |
- 5 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| and after the effective date of this amendatory Act of the 95th |
2 |
| General Assembly upon the expiration of that license.
|
3 |
| (Source: P.A. 94-348, eff. 7-28-05; 95-639, eff. 10-5-07.)
|
4 |
| (225 ILCS 65/65-40)
(was 225 ILCS 65/15-20)
|
5 |
| (Section scheduled to be repealed on January 1, 2018)
|
6 |
| Sec. 65-40. Prescriptive authority.
|
7 |
| (a) A collaborating
physician or podiatrist may, but is not |
8 |
| required to, delegate
prescriptive authority to an advanced |
9 |
| practice
nurse as part of a written collaborative agreement. |
10 |
| This authority may, but is
not required to, include
|
11 |
| prescription of, selection of, orders for, administration of, |
12 |
| storage of, acceptance of samples of, and dispensing over the |
13 |
| counter medications, legend drugs, medical gases, and |
14 |
| controlled
substances categorized as
any Schedule III through , |
15 |
| III-N, IV,
or V controlled substances, as defined in Article II |
16 |
| of the
Illinois Controlled Substances Act, and other |
17 |
| preparations, including, but not limited to, botanical and |
18 |
| herbal remedies. The collaborating physician or podiatrist |
19 |
| must have a valid current Illinois controlled substance license |
20 |
| and federal registration to delegate authority to prescribe |
21 |
| delegated controlled substances.
|
22 |
| (b) To prescribe controlled
substances under this Section, |
23 |
| an advanced practice
nurse must obtain a mid-level practitioner |
24 |
| controlled substance license.
Medication orders shall be
|
25 |
| reviewed
periodically by the collaborating physician or |
|
|
|
SB1371 Engrossed |
- 6 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| podiatrist.
|
2 |
| (c) The collaborating physician or podiatrist shall file |
3 |
| with the
Department notice of delegation of prescriptive |
4 |
| authority
and
termination of such delegation, in accordance |
5 |
| with rules of the Department.
Upon receipt of this notice |
6 |
| delegating authority to prescribe any Schedule III through ,
|
7 |
| III-N, IV, or V controlled substances, the licensed advanced |
8 |
| practice nurse shall be
eligible to register for a mid-level |
9 |
| practitioner controlled substance license
under Section 303.05 |
10 |
| of the Illinois Controlled Substances Act.
|
11 |
| (d) In addition to the requirements of subsections (a), |
12 |
| (b), and (c) of this Section, a collaborating physician may, |
13 |
| but is not required to, delegate authority to an advanced |
14 |
| practice nurse to prescribe any Schedule II or II-N controlled |
15 |
| substances, if all of the following conditions apply: |
16 |
| (1) No more than 5 Schedule II or II-N controlled |
17 |
| substances by oral dosage may be delegated. |
18 |
| (2) Any delegation must be controlled substances that |
19 |
| the collaborating physician prescribes. |
20 |
| (3) Any prescription must be limited to no more than a |
21 |
| 30-day oral dosage, with any continuation authorized only |
22 |
| after prior approval of the collaborating physician. |
23 |
| (4) The advanced practice nurse must discuss the |
24 |
| condition of any patients for whom a controlled substance |
25 |
| is prescribed monthly with the delegating physician.
|
26 |
| (e) Nothing in this Act shall be construed to limit the |
|
|
|
SB1371 Engrossed |
- 7 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| delegation of tasks
or duties by a physician to a licensed |
2 |
| practical nurse, a registered
professional nurse, or other |
3 |
| persons.
|
4 |
| (Source: P.A. 95-639, eff. 10-5-07.)
|
5 |
| Section 10. The Pharmacy Practice Act is amended by |
6 |
| changing Section 4 as follows:
|
7 |
| (225 ILCS 85/4) (from Ch. 111, par. 4124)
|
8 |
| (Section scheduled to be repealed on January 1, 2018)
|
9 |
| Sec. 4. Exemptions. Nothing contained in any Section of |
10 |
| this Act shall
apply
to, or in any manner interfere with:
|
11 |
| (a) the lawful practice of any physician licensed to |
12 |
| practice medicine in
all of its branches, dentist, podiatrist,
|
13 |
| veterinarian, or therapeutically or diagnostically certified |
14 |
| optometrist within
the limits of
his or her license, or prevent |
15 |
| him or her from
supplying to his
or her
bona fide patients
such |
16 |
| drugs, medicines, or poisons as may seem to him appropriate;
|
17 |
| (b) the sale of compressed gases;
|
18 |
| (c) the sale of patent or proprietary medicines and |
19 |
| household remedies
when sold in original and unbroken packages |
20 |
| only, if such patent or
proprietary medicines and household |
21 |
| remedies be properly and adequately
labeled as to content and |
22 |
| usage and generally considered and accepted
as harmless and |
23 |
| nonpoisonous when used according to the directions
on the |
24 |
| label, and also do not contain opium or coca leaves, or any
|
|
|
|
SB1371 Engrossed |
- 8 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| compound, salt or derivative thereof, or any drug which, |
2 |
| according
to the latest editions of the following authoritative |
3 |
| pharmaceutical
treatises and standards, namely, The United |
4 |
| States Pharmacopoeia/National
Formulary (USP/NF), the United |
5 |
| States Dispensatory, and the Accepted
Dental Remedies of the |
6 |
| Council of Dental Therapeutics of the American
Dental |
7 |
| Association or any or either of them, in use on the effective
|
8 |
| date of this Act, or according to the existing provisions of |
9 |
| the Federal
Food, Drug, and Cosmetic Act and Regulations of the |
10 |
| Department of Health
and Human Services, Food and Drug |
11 |
| Administration, promulgated thereunder
now in effect, is |
12 |
| designated, described or considered as a narcotic,
hypnotic, |
13 |
| habit forming, dangerous, or poisonous drug;
|
14 |
| (d) the sale of poultry and livestock remedies in original |
15 |
| and unbroken
packages only, labeled for poultry and livestock |
16 |
| medication;
|
17 |
| (e) the sale of poisonous substances or mixture of |
18 |
| poisonous substances,
in unbroken packages, for nonmedicinal |
19 |
| use in the arts or industries
or for insecticide purposes; |
20 |
| provided, they are properly and adequately
labeled as to |
21 |
| content and such nonmedicinal usage, in conformity
with the |
22 |
| provisions of all applicable federal, state and local laws
and |
23 |
| regulations promulgated thereunder now in effect relating |
24 |
| thereto
and governing the same, and those which are required |
25 |
| under such applicable
laws and regulations to be labeled with |
26 |
| the word "Poison", are also labeled
with the word "Poison" |
|
|
|
SB1371 Engrossed |
- 9 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| printed
thereon in prominent type and the name of a readily |
2 |
| obtainable antidote
with directions for its administration;
|
3 |
| (f) the delegation of limited prescriptive authority by a |
4 |
| physician
licensed to
practice medicine in all its branches to |
5 |
| a physician assistant
under Section 7.5 of the Physician |
6 |
| Assistant Practice Act of 1987. This
delegated authority under |
7 |
| Section 7.5 of the Physician Assistant Practice Act of 1987 may |
8 |
| but is not required to include prescription of
controlled |
9 |
| substances, as defined in Article II of the
Illinois Controlled |
10 |
| Substances Act, in accordance with written guidelines; and
|
11 |
| (g) The delegation of prescriptive authority by a physician
|
12 |
| licensed to practice medicine in all its branches or a licensed |
13 |
| podiatrist to an advanced practice
nurse in accordance with a |
14 |
| written collaborative
agreement under Sections Section 65-35 |
15 |
| and 65-40 of the Nurse Practice Act. This authority, which is |
16 |
| delegated under Section 65-40 of the Nurse Practice Act, may |
17 |
| but is not required to
include the prescription of Schedule |
18 |
| III, IV, or V controlled substances as
defined
in Article II of |
19 |
| the Illinois Controlled Substances Act.
|
20 |
| (Source: P.A. 95-639, eff. 10-5-07 .)
|
21 |
| Section 15. The Illinois Controlled Substances Act is |
22 |
| amended by changing Sections 102 and 303.05 as follows: |
23 |
| (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102) |
24 |
| Sec. 102. Definitions. As used in this Act, unless the |
|
|
|
SB1371 Engrossed |
- 10 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| context
otherwise requires:
|
2 |
| (a) "Addict" means any person who habitually uses any drug, |
3 |
| chemical,
substance or dangerous drug other than alcohol so as |
4 |
| to endanger the public
morals, health, safety or welfare or who |
5 |
| is so far addicted to the use of a
dangerous drug or controlled |
6 |
| substance other than alcohol as to have lost
the power of self |
7 |
| control with reference to his addiction.
|
8 |
| (b) "Administer" means the direct application of a |
9 |
| controlled
substance, whether by injection, inhalation, |
10 |
| ingestion, or any other
means, to the body of a patient, |
11 |
| research subject, or animal (as
defined by the Humane |
12 |
| Euthanasia in Animal Shelters Act) by:
|
13 |
| (1) a practitioner (or, in his presence, by his |
14 |
| authorized agent),
|
15 |
| (2) the patient or research subject at the lawful |
16 |
| direction of the
practitioner, or
|
17 |
| (3) a euthanasia technician as defined by the Humane |
18 |
| Euthanasia in
Animal Shelters Act.
|
19 |
| (c) "Agent" means an authorized person who acts on behalf |
20 |
| of or at
the direction of a manufacturer, distributor, or |
21 |
| dispenser. It does not
include a common or contract carrier, |
22 |
| public warehouseman or employee of
the carrier or warehouseman.
|
23 |
| (c-1) "Anabolic Steroids" means any drug or hormonal |
24 |
| substance,
chemically and pharmacologically related to |
25 |
| testosterone (other than
estrogens, progestins, and |
26 |
| corticosteroids) that promotes muscle growth,
and includes:
|
|
|
|
SB1371 Engrossed |
- 12 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| (xxvii) trenbolone, and
|
2 |
| (xxviii) any salt, ester, or isomer of a drug or |
3 |
| substance described
or listed in this paragraph, if |
4 |
| that salt, ester, or isomer promotes muscle
growth.
|
5 |
| Any person who is otherwise lawfully in possession of an |
6 |
| anabolic
steroid, or who otherwise lawfully manufactures, |
7 |
| distributes, dispenses,
delivers, or possesses with intent to |
8 |
| deliver an anabolic steroid, which
anabolic steroid is |
9 |
| expressly intended for and lawfully allowed to be
administered |
10 |
| through implants to livestock or other nonhuman species, and
|
11 |
| which is approved by the Secretary of Health and Human Services |
12 |
| for such
administration, and which the person intends to |
13 |
| administer or have
administered through such implants, shall |
14 |
| not be considered to be in
unauthorized possession or to |
15 |
| unlawfully manufacture, distribute, dispense,
deliver, or |
16 |
| possess with intent to deliver such anabolic steroid for
|
17 |
| purposes of this Act.
|
18 |
| (d) "Administration" means the Drug Enforcement |
19 |
| Administration,
United States Department of Justice, or its |
20 |
| successor agency.
|
21 |
| (e) "Control" means to add a drug or other substance, or |
22 |
| immediate
precursor, to a Schedule under Article II of this Act |
23 |
| whether by
transfer from another Schedule or otherwise.
|
24 |
| (f) "Controlled Substance" means a drug, substance, or |
25 |
| immediate
precursor in the Schedules of Article II of this Act.
|
26 |
| (g) "Counterfeit substance" means a controlled substance, |
|
|
|
SB1371 Engrossed |
- 13 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| which, or
the container or labeling of which, without |
2 |
| authorization bears the
trademark, trade name, or other |
3 |
| identifying mark, imprint, number or
device, or any likeness |
4 |
| thereof, of a manufacturer, distributor, or
dispenser other |
5 |
| than the person who in fact manufactured, distributed,
or |
6 |
| dispensed the substance.
|
7 |
| (h) "Deliver" or "delivery" means the actual, constructive |
8 |
| or
attempted transfer of possession of a controlled substance, |
9 |
| with or
without consideration, whether or not there is an |
10 |
| agency relationship.
|
11 |
| (i) "Department" means the Illinois Department of Human |
12 |
| Services (as
successor to the Department of Alcoholism and |
13 |
| Substance Abuse) or its successor agency.
|
14 |
| (j) "Department of State Police" means the Department of |
15 |
| State
Police of the State of Illinois or its successor agency.
|
16 |
| (k) "Department of Corrections" means the Department of |
17 |
| Corrections
of the State of Illinois or its successor agency.
|
18 |
| (l) "Department of Professional Regulation" means the |
19 |
| Department
of Professional Regulation of the State of Illinois |
20 |
| or its successor agency.
|
21 |
| (m) "Depressant" or "stimulant substance" means:
|
22 |
| (1) a drug which contains any quantity of (i) |
23 |
| barbituric acid or
any of the salts of barbituric acid |
24 |
| which has been designated as habit
forming under section |
25 |
| 502 (d) of the Federal Food, Drug, and Cosmetic
Act (21 |
26 |
| U.S.C. 352 (d)); or
|
|
|
|
SB1371 Engrossed |
- 14 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| (2) a drug which contains any quantity of (i) |
2 |
| amphetamine or
methamphetamine and any of their optical |
3 |
| isomers; (ii) any salt of
amphetamine or methamphetamine or |
4 |
| any salt of an optical isomer of
amphetamine; or (iii) any |
5 |
| substance which the Department, after
investigation, has |
6 |
| found to be, and by rule designated as, habit forming
|
7 |
| because of its depressant or stimulant effect on the |
8 |
| central nervous
system; or
|
9 |
| (3) lysergic acid diethylamide; or
|
10 |
| (4) any drug which contains any quantity of a substance |
11 |
| which the
Department, after investigation, has found to |
12 |
| have, and by rule
designated as having, a potential for |
13 |
| abuse because of its depressant or
stimulant effect on the |
14 |
| central nervous system or its hallucinogenic
effect.
|
15 |
| (n) (Blank).
|
16 |
| (o) "Director" means the Director of the Department of |
17 |
| State Police or
the Department of Professional Regulation or |
18 |
| his designated agents.
|
19 |
| (p) "Dispense" means to deliver a controlled substance to |
20 |
| an
ultimate user or research subject by or pursuant to the |
21 |
| lawful order of
a prescriber, including the prescribing, |
22 |
| administering, packaging,
labeling, or compounding necessary |
23 |
| to prepare the substance for that
delivery.
|
24 |
| (q) "Dispenser" means a practitioner who dispenses.
|
25 |
| (r) "Distribute" means to deliver, other than by |
26 |
| administering or
dispensing, a controlled substance.
|
|
|
|
SB1371 Engrossed |
- 15 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| (s) "Distributor" means a person who distributes.
|
2 |
| (t) "Drug" means (1) substances recognized as drugs in the |
3 |
| official
United States Pharmacopoeia, Official Homeopathic |
4 |
| Pharmacopoeia of the
United States, or official National |
5 |
| Formulary, or any supplement to any
of them; (2) substances |
6 |
| intended for use in diagnosis, cure, mitigation,
treatment, or |
7 |
| prevention of disease in man or animals; (3) substances
(other |
8 |
| than food) intended to affect the structure of any function of
|
9 |
| the body of man or animals and (4) substances intended for use |
10 |
| as a
component of any article specified in clause (1), (2), or |
11 |
| (3) of this
subsection. It does not include devices or their |
12 |
| components, parts, or
accessories.
|
13 |
| (t-5) "Euthanasia agency" means
an entity certified by the |
14 |
| Department of Professional Regulation for the
purpose of animal |
15 |
| euthanasia that holds an animal control facility license or
|
16 |
| animal
shelter license under the Animal Welfare Act. A |
17 |
| euthanasia agency is
authorized to purchase, store, possess, |
18 |
| and utilize Schedule II nonnarcotic and
Schedule III |
19 |
| nonnarcotic drugs for the sole purpose of animal euthanasia.
|
20 |
| (t-10) "Euthanasia drugs" means Schedule II or Schedule III |
21 |
| substances
(nonnarcotic controlled substances) that are used |
22 |
| by a euthanasia agency for
the purpose of animal euthanasia.
|
23 |
| (u) "Good faith" means the prescribing or dispensing of a |
24 |
| controlled
substance by a practitioner in the regular course of |
25 |
| professional
treatment to or for any person who is under his |
26 |
| treatment for a
pathology or condition other than that |
|
|
|
SB1371 Engrossed |
- 16 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| individual's physical or
psychological dependence upon or |
2 |
| addiction to a controlled substance,
except as provided herein: |
3 |
| and application of the term to a pharmacist
shall mean the |
4 |
| dispensing of a controlled substance pursuant to the
|
5 |
| prescriber's order which in the professional judgment of the |
6 |
| pharmacist
is lawful. The pharmacist shall be guided by |
7 |
| accepted professional
standards including, but not limited to |
8 |
| the following, in making the
judgment:
|
9 |
| (1) lack of consistency of doctor-patient |
10 |
| relationship,
|
11 |
| (2) frequency of prescriptions for same drug by one |
12 |
| prescriber for
large numbers of patients,
|
13 |
| (3) quantities beyond those normally prescribed,
|
14 |
| (4) unusual dosages,
|
15 |
| (5) unusual geographic distances between patient, |
16 |
| pharmacist and
prescriber,
|
17 |
| (6) consistent prescribing of habit-forming drugs.
|
18 |
| (u-1) "Home infusion services" means services provided by a |
19 |
| pharmacy in
compounding solutions for direct administration to |
20 |
| a patient in a private
residence, long-term care facility, or |
21 |
| hospice setting by means of parenteral,
intravenous, |
22 |
| intramuscular, subcutaneous, or intraspinal infusion.
|
23 |
| (v) "Immediate precursor" means a substance:
|
24 |
| (1) which the Department has found to be and by rule |
25 |
| designated as
being a principal compound used, or produced |
26 |
| primarily for use, in the
manufacture of a controlled |
|
|
|
SB1371 Engrossed |
- 17 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| substance;
|
2 |
| (2) which is an immediate chemical intermediary used or |
3 |
| likely to
be used in the manufacture of such controlled |
4 |
| substance; and
|
5 |
| (3) the control of which is necessary to prevent, |
6 |
| curtail or limit
the manufacture of such controlled |
7 |
| substance.
|
8 |
| (w) "Instructional activities" means the acts of teaching, |
9 |
| educating
or instructing by practitioners using controlled |
10 |
| substances within
educational facilities approved by the State |
11 |
| Board of Education or
its successor agency.
|
12 |
| (x) "Local authorities" means a duly organized State, |
13 |
| County or
Municipal peace unit or police force.
|
14 |
| (y) "Look-alike substance" means a substance, other than a |
15 |
| controlled
substance which (1) by overall dosage unit |
16 |
| appearance, including shape,
color, size, markings or lack |
17 |
| thereof, taste, consistency, or any other
identifying physical |
18 |
| characteristic of the substance, would lead a reasonable
person |
19 |
| to believe that the substance is a controlled substance, or (2) |
20 |
| is
expressly or impliedly represented to be a controlled |
21 |
| substance or is
distributed under circumstances which would |
22 |
| lead a reasonable person to
believe that the substance is a |
23 |
| controlled substance. For the purpose of
determining whether |
24 |
| the representations made or the circumstances of the
|
25 |
| distribution would lead a reasonable person to believe the |
26 |
| substance to be
a controlled substance under this clause (2) of |
|
|
|
SB1371 Engrossed |
- 18 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| subsection (y), the court or
other authority may consider the |
2 |
| following factors in addition to any other
factor that may be |
3 |
| relevant:
|
4 |
| (a) statements made by the owner or person in control |
5 |
| of the substance
concerning its nature, use or effect;
|
6 |
| (b) statements made to the buyer or recipient that the |
7 |
| substance may
be resold for profit;
|
8 |
| (c) whether the substance is packaged in a manner |
9 |
| normally used for the
illegal distribution of controlled |
10 |
| substances;
|
11 |
| (d) whether the distribution or attempted distribution |
12 |
| included an
exchange of or demand for money or other |
13 |
| property as consideration, and
whether the amount of the |
14 |
| consideration was substantially greater than the
|
15 |
| reasonable retail market value of the substance.
|
16 |
| Clause (1) of this subsection (y) shall not apply to a |
17 |
| noncontrolled
substance in its finished dosage form that was |
18 |
| initially introduced into
commerce prior to the initial |
19 |
| introduction into commerce of a controlled
substance in its |
20 |
| finished dosage form which it may substantially resemble.
|
21 |
| Nothing in this subsection (y) prohibits the dispensing or |
22 |
| distributing
of noncontrolled substances by persons authorized |
23 |
| to dispense and
distribute controlled substances under this |
24 |
| Act, provided that such action
would be deemed to be carried |
25 |
| out in good faith under subsection (u) if the
substances |
26 |
| involved were controlled substances.
|
|
|
|
SB1371 Engrossed |
- 19 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| Nothing in this subsection (y) or in this Act prohibits the |
2 |
| manufacture,
preparation, propagation, compounding, |
3 |
| processing, packaging, advertising
or distribution of a drug or |
4 |
| drugs by any person registered pursuant to
Section 510 of the |
5 |
| Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
|
6 |
| (y-1) "Mail-order pharmacy" means a pharmacy that is |
7 |
| located in a state
of the United States, other than Illinois, |
8 |
| that delivers, dispenses or
distributes, through the United |
9 |
| States Postal Service or other common
carrier, to Illinois |
10 |
| residents, any substance which requires a prescription.
|
11 |
| (z) "Manufacture" means the production, preparation, |
12 |
| propagation,
compounding, conversion or processing of a |
13 |
| controlled substance other than methamphetamine, either
|
14 |
| directly or indirectly, by extraction from substances of |
15 |
| natural origin,
or independently by means of chemical |
16 |
| synthesis, or by a combination of
extraction and chemical |
17 |
| synthesis, and includes any packaging or
repackaging of the |
18 |
| substance or labeling of its container, except that
this term |
19 |
| does not include:
|
20 |
| (1) by an ultimate user, the preparation or compounding |
21 |
| of a
controlled substance for his own use; or
|
22 |
| (2) by a practitioner, or his authorized agent under |
23 |
| his
supervision, the preparation, compounding, packaging, |
24 |
| or labeling of a
controlled substance:
|
25 |
| (a) as an incident to his administering or |
26 |
| dispensing of a
controlled substance in the course of |
|
|
|
SB1371 Engrossed |
- 20 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| his professional practice; or
|
2 |
| (b) as an incident to lawful research, teaching or |
3 |
| chemical
analysis and not for sale.
|
4 |
| (z-1) (Blank).
|
5 |
| (aa) "Narcotic drug" means any of the following, whether |
6 |
| produced
directly or indirectly by extraction from substances |
7 |
| of natural origin,
or independently by means of chemical |
8 |
| synthesis, or by a combination of
extraction and chemical |
9 |
| synthesis:
|
10 |
| (1) opium and opiate, and any salt, compound, |
11 |
| derivative, or
preparation of opium or opiate;
|
12 |
| (2) any salt, compound, isomer, derivative, or |
13 |
| preparation thereof
which is chemically equivalent or |
14 |
| identical with any of the substances
referred to in clause |
15 |
| (1), but not including the isoquinoline alkaloids
of opium;
|
16 |
| (3) opium poppy and poppy straw;
|
17 |
| (4) coca leaves and any salts, compound, isomer, salt |
18 |
| of an isomer,
derivative, or preparation of coca leaves |
19 |
| including cocaine or ecgonine,
and any salt, compound, |
20 |
| isomer, derivative, or preparation thereof which is
|
21 |
| chemically equivalent or identical with any of these |
22 |
| substances, but not
including decocainized coca leaves or |
23 |
| extractions of coca leaves which do
not contain cocaine or |
24 |
| ecgonine (for the purpose of this paragraph, the
term |
25 |
| "isomer" includes optical, positional and geometric |
26 |
| isomers).
|
|
|
|
SB1371 Engrossed |
- 21 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| (bb) "Nurse" means a registered nurse licensed under the
|
2 |
| Nurse Practice Act.
|
3 |
| (cc) (Blank).
|
4 |
| (dd) "Opiate" means any substance having an addiction |
5 |
| forming or
addiction sustaining liability similar to morphine |
6 |
| or being capable of
conversion into a drug having addiction |
7 |
| forming or addiction sustaining
liability.
|
8 |
| (ee) "Opium poppy" means the plant of the species Papaver
|
9 |
| somniferum L., except its seeds.
|
10 |
| (ff) "Parole and Pardon Board" means the Parole and Pardon |
11 |
| Board of
the State of Illinois or its successor agency.
|
12 |
| (gg) "Person" means any individual, corporation, |
13 |
| mail-order pharmacy,
government or governmental subdivision or |
14 |
| agency, business trust, estate,
trust, partnership or |
15 |
| association, or any other entity.
|
16 |
| (hh) "Pharmacist" means any person who holds a license or |
17 |
| certificate of
registration as a registered pharmacist, a local |
18 |
| registered pharmacist
or a registered assistant pharmacist |
19 |
| under the Pharmacy Practice Act.
|
20 |
| (ii) "Pharmacy" means any store, ship or other place in |
21 |
| which
pharmacy is authorized to be practiced under the Pharmacy |
22 |
| Practice Act.
|
23 |
| (jj) "Poppy straw" means all parts, except the seeds, of |
24 |
| the opium
poppy, after mowing.
|
25 |
| (kk) "Practitioner" means a physician licensed to practice |
26 |
| medicine in all
its branches, dentist, optometrist, |
|
|
|
SB1371 Engrossed |
- 22 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| podiatrist,
veterinarian, scientific investigator, pharmacist, |
2 |
| physician assistant,
advanced practice nurse,
licensed |
3 |
| practical
nurse, registered nurse, hospital, laboratory, or |
4 |
| pharmacy, or other
person licensed, registered, or otherwise |
5 |
| lawfully permitted by the
United States or this State to |
6 |
| distribute, dispense, conduct research
with respect to, |
7 |
| administer or use in teaching or chemical analysis, a
|
8 |
| controlled substance in the course of professional practice or |
9 |
| research.
|
10 |
| (ll) "Pre-printed prescription" means a written |
11 |
| prescription upon which
the designated drug has been indicated |
12 |
| prior to the time of issuance.
|
13 |
| (mm) "Prescriber" means a physician licensed to practice |
14 |
| medicine in all
its branches, dentist, optometrist, podiatrist |
15 |
| or
veterinarian who issues a prescription, a physician |
16 |
| assistant who
issues a
prescription for a Schedule III, IV, or |
17 |
| V controlled substance
in accordance
with Section 303.05 and |
18 |
| the written guidelines required under Section 7.5
of the
|
19 |
| Physician Assistant Practice Act of 1987, or an advanced |
20 |
| practice
nurse with prescriptive authority delegated under |
21 |
| Section 65-40 of the Nurse Practice Act and in accordance with |
22 |
| Section 303.05 , a written delegation,
and a written
|
23 |
| collaborative agreement under Section 65-35 of the Nurse |
24 |
| Practice Act.
|
25 |
| (nn) "Prescription" means a lawful written, facsimile, or |
26 |
| verbal order
of
a physician licensed to practice medicine in |
|
|
|
SB1371 Engrossed |
- 23 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| all its branches,
dentist, podiatrist or veterinarian for any |
2 |
| controlled
substance, of an optometrist for a Schedule III, IV, |
3 |
| or V controlled substance in accordance with Section 15.1 of |
4 |
| the Illinois Optometric Practice Act of 1987, of a physician |
5 |
| assistant for a Schedule III, IV, or V
controlled substance
in |
6 |
| accordance with Section 303.05 and the written guidelines |
7 |
| required under
Section 7.5 of the
Physician Assistant Practice |
8 |
| Act of 1987, or of an advanced practice
nurse with prescriptive |
9 |
| authority delegated under Section 65-40 of the Nurse Practice |
10 |
| Act who issues a prescription for a Schedule III, IV, or V
|
11 |
| controlled substance in accordance
with
Section 303.05 , a |
12 |
| written delegation, and a written collaborative agreement |
13 |
| under Section 65-35 of the Nurse Practice Act.
|
14 |
| (oo) "Production" or "produce" means manufacture, |
15 |
| planting,
cultivating, growing, or harvesting of a controlled |
16 |
| substance other than methamphetamine.
|
17 |
| (pp) "Registrant" means every person who is required to |
18 |
| register
under Section 302 of this Act.
|
19 |
| (qq) "Registry number" means the number assigned to each |
20 |
| person
authorized to handle controlled substances under the |
21 |
| laws of the United
States and of this State.
|
22 |
| (rr) "State" includes the State of Illinois and any state, |
23 |
| district,
commonwealth, territory, insular possession thereof, |
24 |
| and any area
subject to the legal authority of the United |
25 |
| States of America.
|
26 |
| (ss) "Ultimate user" means a person who lawfully possesses |
|
|
|
SB1371 Engrossed |
- 24 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| a
controlled substance for his own use or for the use of a |
2 |
| member of his
household or for administering to an animal owned |
3 |
| by him or by a member
of his household.
|
4 |
| (Source: P.A. 94-556, eff. 9-11-05; 95-242, eff. 1-1-08; |
5 |
| 95-639, eff. 10-5-07; 95-689, eff. 10-29-07; 95-876, eff. |
6 |
| 8-21-08.)
|
7 |
| (720 ILCS 570/303.05)
|
8 |
| Sec. 303.05. Mid-level practitioner registration.
|
9 |
| (a) The Department of Professional Regulation shall |
10 |
| register licensed
physician assistants and licensed advanced |
11 |
| practice nurses to prescribe and
dispense Schedule
III, IV, or |
12 |
| V controlled substances under Section 303 and euthanasia
|
13 |
| agencies to purchase, store, or administer animal euthanasia |
14 |
| drugs under the
following circumstances:
|
15 |
| (1) with respect to physician assistants or advanced |
16 |
| practice nurses ,
|
17 |
| (A) the physician assistant or advanced practice |
18 |
| nurse has been
delegated
prescriptive authority to |
19 |
| prescribe any Schedule III through V controlled |
20 |
| substances by a physician licensed to practice |
21 |
| medicine in all its
branches in accordance with Section |
22 |
| 7.5 of the Physician Assistant Practice Act
of 1987 or |
23 |
| Section 65-40 of the Nurse Practice Act ;
and
|
24 |
| (B) the physician assistant or advanced practice |
25 |
| nurse has
completed the
appropriate application forms |
|
|
|
SB1371 Engrossed |
- 25 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| and has paid the required fees as set by rule;
or
|
2 |
| (2) with respect to advanced practice nurses, |
3 |
| (A) the advanced practice nurse has been delegated
|
4 |
| authority to prescribe any Schedule III through V |
5 |
| controlled substances by a physician licensed to |
6 |
| practice medicine in all its branches or a podiatrist |
7 |
| in accordance with Section 65-40 of the Nurse Practice
|
8 |
| Act. The advanced practice nurse has completed the
|
9 |
| appropriate application forms and has paid the |
10 |
| required
fees as set by rule; or |
11 |
| (B) the advanced practice nurse has been delegated
|
12 |
| authority by a collaborating physician licensed to |
13 |
| practice medicine in all its branches to prescribe or |
14 |
| dispense Schedule II controlled substances through a |
15 |
| written delegation of authority and under the |
16 |
| following conditions: |
17 |
| (i) no more than 5 Schedule II controlled |
18 |
| substances by oral dosage may be delegated; |
19 |
| (ii) any delegation must be of controlled |
20 |
| substances prescribed by the collaborating |
21 |
| physician; |
22 |
| (iii) all prescriptions must be limited to no |
23 |
| more than a 30-day oral dosage, with any |
24 |
| continuation authorized only after prior approval |
25 |
| of the collaborating physician; |
26 |
| (iv) the advanced practice nurse must discuss |
|
|
|
SB1371 Engrossed |
- 26 - |
LRB096 10807 ASK 21022 b |
|
|
1 |
| the condition of any patients for whom a controlled |
2 |
| substance is prescribed monthly with the |
3 |
| delegating physician; and |
4 |
| (v) the advanced practice nurse must have |
5 |
| completed the appropriate application forms and |
6 |
| paid the required fees as set by rule; or |
7 |
| (3) (2) with respect to animal euthanasia agencies, the |
8 |
| euthanasia agency has
obtained a license from the |
9 |
| Department of
Professional Regulation and obtained a |
10 |
| registration number from the
Department.
|
11 |
| (b) The mid-level practitioner shall only be licensed to |
12 |
| prescribe those
schedules of controlled substances for which a |
13 |
| licensed physician or licensed podiatrist has delegated
|
14 |
| prescriptive authority, except that an animal a euthanasia |
15 |
| agency does not have any
prescriptive authority.
A physician |
16 |
| assistant and an advanced practice nurse are prohibited from |
17 |
| prescribing medications and controlled substances not set |
18 |
| forth in the required written delegation of authority.
|
19 |
| (c) Upon completion of all registration requirements, |
20 |
| physician
assistants, advanced practice nurses, and animal |
21 |
| euthanasia agencies shall be issued a
mid-level practitioner
|
22 |
| controlled substances license for Illinois.
|
23 |
| (Source: P.A. 95-639, eff. 10-5-07.)
|
24 |
| Section 99. Effective date. This Act takes effect upon |
25 |
| becoming law.
|